Vectibix clinical trials (correction)
Executive Summary
Amgen said it is continuing to study Vectibix (panitumumab), which failed to show survival benefits in a Phase IIIb trial, as a single biologic combined with chemotherapy in two Phase III trials in the first-and second-line of metastatic colorectal cancer. A previous article suggests that Vectibix failed to show survival benefits in a Phase IV commitment (1"The Pink Sheet" Aug. 20, 2007, p. 16). Phase IV commitments for Vectibix are progressing well, notably the registrational Phase III trial in the second-line of metastatic colorectal cancer, Amgen says...
You may also be interested in...
Accelerated “De-proval”? FDA May Be Ready To Withdraw Subpart H Drug
FDA is moving towards potentially withdrawing, for the first time, a drug brought to market under the Subpart H accelerated approval mechanism
New EU Approvals
The Pink Sheet's list of EU centralized approvals of new active substances has been updated to add two new products, including Ryzneuta, Evive Biotechnology's treatment for chemotherapy-induced neutropenia.
Pair Of Deaths Linked To Recalled Vyaire Medical Respiratory Devices
The US FDA has labelled a recall of more than 6 million Airlife respiratory support devices class I. The recall covers devices manufactured in 2017 or earlier that can fail to provide adequate ventilation.